News Search Results
Oct 20, 2025, 11:00 ET Plug and Play Lifetech Announces Inaugural Batch of 12 Innovative Startups in Indianapolis
a leader in life sciences innovation. The program supports startups developing breakthroughs in therapeutics, diagnostics, medical devices, and biotechnology through mentorship, investor access, and corporate collaboration. To learn more about Plug and Play Lifetech, visit:
More news about: Plug and Play
Oct 20, 2025, 10:34 ET MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025
CAMBRIDGE, Mass., Oct. 20, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that two abstracts highlighting data on DA-1726, a novel, dual oxyntomodulin
More news about: MetaVia Inc.
Oct 20, 2025, 10:01 ET Bone Regeneration Market to Reach $6.0 Billion by 2027 in the short term and $8.4 Billion by 2034 Globally, at 4.9% CAGR: Allied Market Research
differentiated technologies. In October 2024, Enovis announced its strategic partnership with Ossium Health, a clinical-stage biotechnology company, to distribute OssiGraft and OssiGraft Prime cryopreserved viable bone matrix (VBX) allografts through Enovis' extensive sales network.
More news about: Allied Market Research
Oct 20, 2025, 09:35 ET New NYC 'Liver ICU' Lab Transforming Liver Disease Treatments
NEW YORK, Oct. 20, 2025 /PRNewswire/ -- Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, has opened a unique perfusion 'Liver ICU' lab in the Alexandria Centre for Life Sciences.
More news about: Ochre Bio
Oct 20, 2025, 09:28 ET MLTX INVESTOR DEADLINE: MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
later than December 15, 2025. CASE ALLEGATIONS: MoonLake is a clinical stage biotechnology company that focuses on developing therapies for inflammatory skin and joint diseases. According to the complaint, MoonLake's sole drug candidate
More news about: Robbins Geller Rudman & Dowd LLP
Oct 20, 2025, 09:00 ET Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada
About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated
More news about: Oncolytics Biotech® Inc.
Oct 20, 2025, 08:33 ET GlycoNex Abstract on Glycan-Directed ADC GNX1021 Accepted for Presentation at AACR-NCI-EORTC 2025
GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that an abstract describing preclinical research on
More news about: GlycoNex, Inc.
Oct 20, 2025, 08:33 ET Surf Bio to Present SnapShot™ Platform at PODD 2025, Showcasing Potential to Transform Subcutaneous Delivery of High-Dose Biologic Therapies
potential to redefine the accessibility, economics, and patient experience of biologic treatment. We look forward to connecting with pharmaceutical and biotechnology leaders at PODD 2025 to explore partnership opportunities that can leverage this platform." Surf Bio will be available throughout
More news about: Surf Bio, Inc.
Oct 20, 2025, 08:30 ET Driving Success in Therapeutics with Recombinant Antibody Production, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 20, 2025, 08:30 ET From Signals to Strategy: The Next Chapter of Digital Biomarkers, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 20, 2025, 08:25 ET Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Chinese National Intellectual Property Administration (CNIPA)
More news about: Anixa Biosciences, Inc.
Oct 20, 2025, 07:00 ET HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025
SAN FRANCISCO, Oct. 20, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies, today announced that new clinical data from HCB101, its differentiated, engineered SIRPα-Fc
More news about: HanchorBio Inc.
Oct 20, 2025, 07:00 ET Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
CAMBRIDGE, Mass., Oct. 20, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced final results from Part B of the DeFianCe study (
More news about: Leap Therapeutics, Inc.
Oct 20, 2025, 06:55 ET Protocatechuic Acid Market worth $24.0 million by 2030 - Exclusive Report by MarketsandMarkets™
skin-protective capabilities are increasingly utilized in the booming personal care and cosmetics sector. Moreover, technological advancements in biotechnology and green chemistry are enabling more sustainable and cost-effective production processes, thereby strengthening PCA's position as a vital ingredient
More news about: MarketsandMarkets
Oct 20, 2025, 06:13 ET Groundbreaking Study in the Journal of Clinical Investigation Advances Cell Therapy for Huntington's Disease Treatment
therapies against neurodegenerative disorders." [About Unixell Biotechnology] Shanghai Unixell Biotechnology, founded in 2021, focuses on developing cell therapies for neurological diseases such as Parkinson's disease
More news about: UniXell Biotechnology
Oct 20, 2025, 05:00 ET FDA Grants Orphan Drug Designation to Cellenkos' CK0803 Tregs for Treatment of Amyotrophic Lateral Sclerosis
HOUSTON, Oct. 20, 2025 /PRNewswire/ -- Cellenkos® Inc., a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf, T regulatory (Treg) cell therapies for autoimmune diseases and inflammatory disorders especially
More news about: Cellenkos, Inc.
Oct 20, 2025, 03:41 ET AgiBot Shines at GITEX GLOBAL 2025, Developing Comprehensive Humanoid Solutions and Connecting Intelligent Future
edition, GITEX GLOBAL stands as the world's most established and iconic large-scale tech exhibition exploring breakthroughs in AI, quantum computing, biotechnology and sustainable technology that are transforming global infrastructure and growth. Built on the foundation of robot ontology
More news about: AgiBot Innovation (Shanghai) Technology Co.,Ltd.
Oct 19, 2025, 20:10 ET Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Oct 19, 2025, 19:00 ET Clover Appoints Nicholas Jackson, Ph.D., as President of Global R&D and Alliances
Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced the appointment
More news about: Clover Biopharma
Oct 19, 2025, 17:15 ET CLARINS & V MAGAZINE CELEBRATE HIGH-PERFORMANCE BEAUTY WITH A STAR-STUDDED GOLDEN HOUR EVENT IN AUSTIN
smooths, and brightens in just 30 seconds. Formulated with a retinol-like technology combining botanical actives with the latest advancements in biotechnology for instant, high-performance results. Guests enjoyed a cocktail hour bathed in golden light inspired by Double Serum's signature
More news about: Clarins USA
Oct 19, 2025, 10:49 ET iOncologi Secures Foundational U.S. Patent as Landmark Studies Link COVID19 mRNA Vaccines to Improved Survival with Cancer Immunotherapy
GAINESVILLE, Fla., Oct. 19, 2025 /PRNewswire/ -- iOncologi, Inc., a biotechnology company developing next-generation RNA-based cancer immunotherapies, today announced that the United States Patent and Trademark Office (USPTO)
More news about: iOncologi, Inc.
Oct 19, 2025, 08:45 ET SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at ESMO
REDMOND, Wash., Oct. 19, 2025 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, today announced positive topline results from the BL-B01D1-301 trial. The trial has met one of the dual primary endpoints (BICR-assessed
More news about: SystImmune, Inc.
Oct 18, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Jasper Therapeutics, Inc. and Certain Officers - JSPR
here for information about joining the class action] Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ("CSU"), Chronic Inducible
More news about: Pomerantz LLP
Oct 18, 2025, 01:00 ET SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025
SINGAPORE, Oct. 18, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing next-generation immunotherapies for infectious diseases and their associated cancers, announced the presentation of first-in-human
More news about: SCG Cell Therapy Pte Ltd
Oct 18, 2025, 01:00 ET SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025
SINGAPORE, Oct. 18, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing next-generation immunotherapies for infectious diseases and their associated cancers, announced the presentation of first-in-human
More news about: SCG Cell Therapy Pte Ltd